The "Synovial Sarcoma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offeringA groundbreaking insight into the Synovial Sarcoma pipeline has been revealed for the year ...

Previous studies reported that cellular communication network factor 1 (CCN1) is overexpressed in the endothelial cells and synovial tissue of patients with rheumatoid arthritis (RA). French ...

Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

MRCLS had clinical responses with lete-celResults include six complete responses (6/64); twenty-one partial responses ...

Following strong treatment response data for Adaptimmune’s lete-cel, the biotech is planning to initiate a rolling BLA ...

Adaptimmune Therapeutics is prepping for another FDA submission after 42% of patients with sarcoma responded to the company's ...

Adaptimmune Therapeutics’ lete-cel data achieves primary endpoint in pivotal phase 2 IGNYTE-ESO trial: Philadelphia Friday, November 15, 2024, 13:00 Hrs [IST] Adaptimmune Therap ...

Adaptimmune’s Phase II trial of lete-cel showed a 42% response rate in synovial sarcoma and MRCLS, with strong median ...